google-site-verification: googlec7193c3de77668c9.html

Recent Posts

Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy

[ Credit: Unsplash/CC0 Public Domain The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026. Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease characterized by misfolded transthyretin …

Read More »
Available for Amazon Prime